{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:56:40Z","timestamp":1789419400371,"version":"build-2803163510"},"reference-count":94,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular pathogenesis and which patients may have greatest risk of progression or vascular events. However, it has been more than a decade since a new therapy has been approved for ET.\u00a0We are beginning to understand more comprehensively both the heterogeneity of this disease, which is largely driven by driver mutation status, as well as the effect of disease-related symptoms, such as fatigue, on patients. In this review we provide a practical overview of diagnosis and management of ET with focus on challenging patient scenarios and some consideration of what comprehensive care might entail. Finally, we also discuss newer therapies and how these might be assessed.<\/jats:p>","DOI":"10.1182\/blood.2022017625","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T16:35:29Z","timestamp":1668530129000},"page":"1943-1953","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Essential thrombocythemia: challenges in clinical practice and future prospects"],"prefix":"10.1182","volume":"141","author":[{"given":"Anna L.","family":"Godfrey","sequence":"first","affiliation":[{"name":"1Department of Haematology and Haemato-oncology Diagnostics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Green","sequence":"additional","affiliation":[{"name":"2Department of Cellular Pathology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"3Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2023110216020050400_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF01891529","article-title":"Haemorrhagische thrombocythamie bei vascularer schrumpfmilz","volume":"293","author":"Epstein","year":"1934","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"4","key":"2023110216020050400_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"2023110216020050400_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2023110216020050400_bib4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023110216020050400_bib5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2023110216020050400_bib6","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"issue":"3","key":"2023110216020050400_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guideline for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2023110216020050400_bib8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023110216020050400_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"9501","key":"2023110216020050400_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"2023110216020050400_bib11","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"issue":"25","key":"2023110216020050400_bib12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023110216020050400_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"2023110216020050400_bib14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W&gt;L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2023110216020050400_bib15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110216020050400_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12986","article-title":"Modification of British committee for standards in haematology diagnostic criteria for essential thrombocythaemia","volume":"167","author":"Harrison","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110216020050400_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023110216020050400_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2023110216020050400_bib19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/jclinpath-2020-206570","article-title":"Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort","volume":"74","author":"Michail","year":"2021","journal-title":"J\u00a0Clin Pathol"},{"issue":"14","key":"2023110216020050400_bib20","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2020002230","article-title":"Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients","volume":"4","author":"Sirinukunwattana","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"2023110216020050400_bib21","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"17","key":"2023110216020050400_bib22","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/bloodadvances.2022007201","article-title":"Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs","volume":"6","author":"Sobas","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2023110216020050400_bib23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"23","key":"2023110216020050400_bib24","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023110216020050400_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur J Haematol"},{"issue":"18","key":"2023110216020050400_bib26","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023110216020050400_bib27","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023110216020050400_bib28","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ajh.26332","article-title":"Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients","volume":"96","author":"Loscocco","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"2023110216020050400_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"11","key":"2023110216020050400_bib30","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023110216020050400_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110216020050400_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023110216020050400_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"issue":"26","key":"2023110216020050400_bib34","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2023110216020050400_bib35","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2023110216020050400_bib36","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.2019001318","article-title":"From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms","volume":"134","author":"Stein","year":"2019","journal-title":"Blood"},{"issue":"33","key":"2023110216020050400_bib37","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023110216020050400_bib38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2023110216020050400_bib39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bjh.16988","article-title":"Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia","volume":"192","author":"Alvarez-Larr\u00e1n","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"2023110216020050400_bib40","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1016\/S2352-3026(21)00204-0","article-title":"Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet","volume":"8","author":"Alvarez-Larr\u00e1n","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023110216020050400_bib41","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larran","year":"2016","journal-title":"Haematologica"},{"issue":"34","key":"2023110216020050400_bib42","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2018.78.8414","article-title":"Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features","volume":"36","author":"Godfrey","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"2023110216020050400_bib43","unstructured":"National Comprehensive Cancer Network\n          . NCCN guidelines: myeloproliferative neoplasms, version 2, 2022.. Accessed 15 August 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"issue":"2","key":"2023110216020050400_bib44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023110216020050400_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A\u00a0randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"issue":"24","key":"2023110216020050400_bib46","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/CIR.0b013e318202f701","article-title":"ACCF\/ACG\/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents","volume":"122","author":"Abraham","year":"2010","journal-title":"Circulation"},{"issue":"17","key":"2023110216020050400_bib47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2023110216020050400_bib48","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2023110216020050400_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"10","key":"2023110216020050400_bib50","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023110216020050400_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023110216020050400_bib52","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A\u00a0unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2023110216020050400_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3324\/haematol.2017.174672","article-title":"Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study","volume":"103","author":"Birgeg\u00e5rd","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"2023110216020050400_bib54","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"2023110216020050400_bib55","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.1016\/j.clml.2013.05.015","article-title":"Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide","volume":"13","author":"Ahn","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2023110216020050400_bib56","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1080\/10428190802353625","article-title":"The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy","volume":"49","author":"D\u2019adda","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2023110216020050400_bib57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2012.083097","article-title":"Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study","volume":"99","author":"Gugliotta","year":"2014","journal-title":"Haematologica"},{"issue":"19","key":"2023110216020050400_bib58","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A\u00a0randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2023110216020050400_bib59","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2023110216020050400_bib60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.15968","article-title":"Essential thrombocythaemia treated with recombinant interferon: \u201creal world\u201d United Kingdom referral centre experience","volume":"186","author":"Desterro","year":"2019","journal-title":"Br J Haematol"},{"issue":"24","key":"2023110216020050400_bib61","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2023110216020050400_bib62","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2021010986","article-title":"Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms","volume":"138","author":"Mosca","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023110216020050400_bib63","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1182\/bloodadvances.2021004856","article-title":"Genomic profiling of a randomized trial of interferon-\u03b1 vs hydroxyurea in MPN reveals mutation-specific responses","volume":"6","author":"Knudsen","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023110216020050400_bib64","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"27","key":"2023110216020050400_bib65","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2217\/fon-2022-0596","article-title":"SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"issue":"12","key":"2023110216020050400_bib66","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Ann Hematol"},{"issue":"5","key":"2023110216020050400_bib67","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1038\/bcj.2016.34","article-title":"Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience","volume":"6","author":"Begna","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023110216020050400_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10428194.2016.1187269","article-title":"Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea","volume":"58","author":"Douglas","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023110216020050400_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-018-0091-6","article-title":"Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"8","author":"Renso","year":"2018","journal-title":"Blood Cancer J"},{"issue":"15","key":"2023110216020050400_bib70","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2023110216020050400_bib71","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"2023110216020050400_bib72","first-page":"S198","article-title":"BET inhibitor Pelabresib (CPI-0610) combined with Ruxolitinib in patients with myelofibrosis \u2014 JAK inhibitor-na\u00efve or with suboptimal response to Ruxolitinib \u2014 preliminary data from the MANIFEST study","volume":"357062","author":"Mascarenhas","year":"2022","journal-title":"EHA Libr"},{"key":"2023110216020050400_bib73","first-page":"P1033","article-title":"A\u00a0phase 2 study of the LSD1 inhbitor IMG-7289 (Bomedemstat) for the treatment of essential thrombocythemia (ET)","volume":"357892","author":"Palandri","year":"2022","journal-title":"EHA Libr"},{"issue":"2","key":"2023110216020050400_bib74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstr\u00f6m","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2023110216020050400_bib75","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/bjh.17850","article-title":"The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy","volume":"196","author":"Strickland","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2023110216020050400_bib76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.blre.2016.11.001","article-title":"After 10 years of JAK2V617F: disease biology and current management strategies in polycythaemia vera","volume":"31","author":"Grinfeld","year":"2017","journal-title":"Blood Rev"},{"issue":"4","key":"2023110216020050400_bib77","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/bjh.13329","article-title":"Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort","volume":"169","author":"Randi","year":"2015","journal-title":"Br J Haematol"},{"key":"2023110216020050400_bib78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3332\/ecancer.2016.608","article-title":"An Association of Cancer Physicians\u2019 strategy for improving services and outcomes for cancer patients","volume":"10","author":"Baird","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"11","key":"2023110216020050400_bib79","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1002\/cncr.21891","article-title":"Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia","volume":"106","author":"Gangat","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"2023110216020050400_bib80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A\u00a0guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: a British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2023110216020050400_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.14289","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study","volume":"175","author":"Alimam","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2023110216020050400_bib82","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.25748","article-title":"Pregnancy outcomes in myeloproliferative neoplasms: a Mayo clinic report on 102 pregnancies","volume":"95","author":"Gangat","year":"2020","journal-title":"Am J Hematol"},{"issue":"4 pt 2","key":"2023110216020050400_bib83","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2006-942763","article-title":"Essential thrombocythemia\/polycythemia vera and pregnancy: the need for an observational study in Europe","volume":"32","author":"Griesshammer","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2023110216020050400_bib84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.16453","article-title":"How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy","volume":"189","author":"Robinson","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2023110216020050400_bib85","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2023110216020050400_bib86","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant\u2019Antonio","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2023110216020050400_bib87","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023110216020050400_bib88","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb Haemost"},{"issue":"3","key":"2023110216020050400_bib89","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/bjh.16485","article-title":"Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK","volume":"189","author":"Curto-Garcia","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2023110216020050400_bib90","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023110216020050400_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A\u00a0systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Hamuly\u00e1k","year":"2021","journal-title":"Blood Adv"},{"key":"2023110216020050400_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thromres.2022.05.015","article-title":"Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms","volume":"216","author":"Herbreteau","year":"2022","journal-title":"Thromb Res"},{"issue":"12","key":"2023110216020050400_bib93","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/bloodadvances.2022007397","article-title":"Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study","volume":"6","author":"Ageno","year":"2022","journal-title":"Blood Adv"},{"key":"2023110216020050400_bib94","doi-asserted-by":"crossref","unstructured":"Yu\n              J\n            , ParanagamaD, HannaB, TangJ, ChojeckiA. A retrospective chart review of 809 patients with physician-diagnosed essential thrombocythemia receiving cytoreductive therapy in US community oncology practices. Acta Haematol. Published online 24 August 2022.. https:\/\/doi.org\/10.1159\/000526599.","DOI":"10.1159\/000526599"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/16\/1943\/2087877\/blood_bld-2022-017625-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/16\/1943\/2087877\/blood_bld-2022-017625-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:04:31Z","timestamp":1698926671000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/16\/1943\/493238\/Essential-thrombocythemia-challenges-in-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":94,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017625","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}